Biomarkers Market is Estimated To Witness High Growth Owing To Rising Prevalence of Chronic and Lifestyle Diseases

The biomarkers market is estimated to be valued at US$ 55.59 Bn in 2024 and is expected to exhibit a CAGR of 13.6% over the forecast period 2022- 2030, as highlighted in a new report published by Coherent Market Insights.

The biomarkers market is primarily driven by the rising prevalence of chronic and lifestyle diseases globally. Biomarkers play a crucial role in disease diagnosis, drug development, and personalized medicine. Furthermore, growing applications of biomarkers in cancer management is also propelling the market growth. However, strict regulatory policies and lack of skilled professionals pose a challenge to the market.

Key Market Trends:

Increasing Adoption of Precision Medicine– The adoption of precision medicine has increased significantly over the past few years. Biomarkers play a pivotal role in personalized medicine by helping understand an individual’s specific disease condition and select the right treatment accordingly. This trend is expected to continue in the forecast period thus driving the biomarkers market.

Rising R&D Investments by Pharmaceutical Companies – Major pharmaceutical companies are increasingly investing in biomarkers research and development to accelerate drug development processes. Biomarkers help identify the right patient population for clinical trials and select the most effective drug. This has resulted in rising investments by pharmaceutical players in biomarker development, thereby propelling the market growth. More coverage can be found in the sample copy.

Biomarker Diagnostics Market Opportunity

The biomarker diagnostics market is expected to witness significant growth due to the growing demand for minimally invasive diagnostic procedures. The increasing prevalence of chronic diseases such as cancer and cardiovascular diseases has boosted the adoption of biomarker diagnostics globally. Biomarkers help in early detection of diseases and enable physicians to offer personalized treatment based on disease progression. Further, rising investments by pharmaceutical companies in biomarker research and growing funding from public and private organizations will also contribute to the market growth.

Biomarker Validation and Identification Market Opportunity

With the increasing R&D activities in drug development and focus on precision medicine, the demand for biomarker validation and identification is growing. Biomarkers help pharmaceutical companies in drug development by identifying treatment response groups. Further, with the reduction in cost of sequencing technologies, biomarker discovery from omics data has become feasible. Biomarker identification aids in developing companion diagnostics which help optimize treatment outcomes. The increasing focus on precision medicine will further drive the need for biomarker validation and identification in the coming years.

Key Market Takeaways

The global biomarkers market size was valued at USD 55.59 Bn in 2024 and is anticipated to witness a CAGR of 13.6% during the forecast period 2022 to 2030. The high growth can be attributed to increasing investments in companion diagnostic development by biopharmaceutical companies.

The protein biomarker segment held the largest market share in 2019 owing to wide applications in disease diagnosis. Protein biomarkers help in cancer screening and drug efficacy evaluation.

The diagnosis segment accounted for the highest share of the global biomarkers market in 2019 due to rising cancer incidence globally. Biomarkers assist in sensitive and specific cancer diagnosis.

North America is dominating the global biomarkers market and is expected to maintain its leading position during the forecast period. This can be attributed to presence of major biomarker companies and growing funding for biomarker research in the US.

Competitor Insights:

BioVision Inc
R&D Systems
Abcam
Merck KGaA

Recent Developments in. Biomarkers Market

In 2024, liquid biopsy continued its rise, enabling less invasive cancer monitoring. Genome analysis of cell-free DNA in blood became a key tool to track tumor mutations and guide therapy selection. Companies like Guardant Health, Freenome, and Grail made progress in developing multi-cancer early detection tests from blood samples. By mid-2024, several had initiated clinical validation studies and were moving towards regulatory submissions.

Abbot Diagnostics launched its blood-based PanTher test in 2021 for quantitative detection of the protein phospho-tau217 for assessment of Alzheimer’s disease condition. Fluidic Inc. developed ACEA Biosciences’ xCELLigence platform based impedance technology to measure circulating tumor cells in blood samples of cancer patients. Such fluid biomarkers address key limitations of invasive procedures required for collecting tissue biopsies. They also allow for repeated sampling which is essential for monitoring disease progression or treatment response over time. Full coverage of the report available here.